BridgeMD
New treatment option for Long COVID
Official title Stellate Ganglion Block for Long COVID Symptoms: A Randomized Controlled Trial
ClinicalTrials.gov ID: NCT07374562
What this study is testing
- What it's testing
- This single-center, randomized, controlled, single-blind clinical trial evaluates whether a stellate ganglion block (SGB) using bupivacaine can improve persistent symptoms in adults with long COVID. Participants are assigned in a 1:1 ratio to receive either an ultrasound-guided right-sided SGB or a placebo saline injection delivered to the sternocleidomastoid muscle.
- You might receive a placebo (an inactive treatment) instead of the study drug, decided by chance. You may not know which one you got.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Adults aged 18 years and older
- Positive COVID-19 test confirmed by RT-PCR, antibody test, or antigen test at least 3 months prior to randomization, OR presumed COVID-19 evaluated...
- Persistent symptoms ≥12 weeks after onset of acute COVID-19 AND symptoms lasting at least 2 months. The onset date is defined as the earliest of...
- Post-COVID Functional Status Scale score ≥2.
- Persistent dyspnea ≥2/4 on the mMRC scale at least 12 weeks post-infection.
You likely can't join if
- Prior diagnosis of myalgic encephalomyelitis (ME) or fibromyalgia
- Being on sick leave or disability at the time of the original acute COVID-19 infection.
- Pregnancy or breastfeeding.
- Myocardial infarction within the last 12 weeks.
- Use of anticoagulant therapy.
- Glaucoma.
See the full eligibility criteria
- Adults aged 18 years and older
- Positive COVID-19 test confirmed by RT-PCR, antibody test, or antigen test at least 3 months prior to randomization, OR presumed COVID-19 evaluated by the site investigator (no positive test required) with an acute...
- Persistent symptoms ≥12 weeks after onset of acute COVID-19 AND symptoms lasting at least 2 months. The onset date is defined as the earliest of: date of first positive test, date of first symptoms
- Post-COVID Functional Status Scale score ≥2.
- Persistent dyspnea ≥2/4 on the mMRC scale at least 12 weeks post-infection.
- Persistent COVID-19-related symptoms at the time of randomization.
- If taking medications for fatigue or cognition (e.g., sildenafil, modafinil, armodafinil, guanfacine, N-acetylcysteine, stimulants for ADHD), these must have been initiated and stable for ≥4 weeks prior to...
- Able and willing to provide written informed consent.
- Able to read and understand French.
- Prior diagnosis of myalgic encephalomyelitis (ME) or fibromyalgia
- Being on sick leave or disability at the time of the original acute COVID-19 infection.
- Pregnancy or breastfeeding.
- Myocardial infarction within the last 12 weeks.
- Use of anticoagulant therapy.
- Glaucoma.
- Emphysema requiring home oxygen.
- Cardiac conduction abnormalities.
- Known hypersensitivity to bupivacaine.
- Previous stellate ganglion block (SGB) procedure.
- Any condition that, in the judgment of the medical investigator, makes the patient not a candidate for the proposed treatment.
The study team makes the final eligibility decision.
Where it's taking place
- Trois-Rivières, Quebec, Canada
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Trois-Rivières, Quebec, Canada. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.